Zoetis | ZTS - Cash And Equivalent


Zoetis reported $1.94B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Align Technology USD 1.06B 35.07M Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Dentsply International USD 190M 136M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Henry Schein USD 138M 18M Mar/2026
Idexx Laboratories USD 200.53M 20.46M Mar/2026
Illumina USD 1.42B 368M Dec/2025
IQVIA Holdings USD 1.95B 33M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Laboratory Of America USD 981.1M 448.8M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Neogen USD 159.9M 14.56M Dec/2025
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Phibro Animal Health USD 54.93M 557K Mar/2026
Quest Diagnostics USD 393M 27M Mar/2026
Sanofi EUR 7.66B 1.25B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Zoetis USD 1.94B 369M Mar/2026